Tweets
In this real world EHR-based SLE cohort, AJorge: BEL was assoc w/⬇️risk of damage prog vs. MMF (HR 0.74 [95% CI 0.67-0.83) but no diff bet BEL vs. MTX/AZA at 3yrs
Further prospective studies req'd?
BEL remains an option for non-renal SLE tx.
#ACR23 ABST0606 @RheumNow https://t.co/KabBeXKpvk
sheila ( View Tweet )
2 years 7 months ago
Did you know?
👉APOL1 variants are protective against trypanosomiasis.
👉Despite reassuring renal biopsies, SLE pts with #APOL1 variants had:
⬆️progression to ESRD, ⬆️atherosclerosis, ⬆️osteonecrosis (likely related to endothel dysfnx) #ACR23 @ashira_md @RheumNow #DuboisLecture https://t.co/w1lnGMPFAQ
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 7 months ago
Abs#0726 #ACR23 @RheumNow
MSUS recs in Canadian Rheum training 🇨🇦:
Focus MSUS exam of hands/wrists/feet: ID effusion, synov, erosions v osteophyte, tenosyn
Limited MSUS of knee/ankle for effusion
@USSONAR_Rh @MymaAlbaydaMD
Agree: MSUS should be part of rheum training for all https://t.co/UNPpAA1p0V
Eric Dein ( View Tweet )
2 years 7 months ago
Real world data on low dose PEXIVAS steroid by Nagle et al. Increased risk of progression/relapse/death/ESKD in those with severe GPA/MPA HR 1.72. More marked in those with creat>300 or with RTX induction Abstr#0725 #ACR23 @RheumNow https://t.co/vTXVZfjbXx https://t.co/4FuMjxOuyB
Richard Conway ( View Tweet )
2 years 7 months ago
Should there be a minimum ultrasound training as competencies in rheumatology training? Abst0726 #ACR23 @ACRheum @RheumNow #RheumEd #POCUS https://t.co/mqdcPEeMYW
Janet Pope ( View Tweet )
2 years 7 months ago
INVIGORATE-2 RCT of IV secukinumab in PsA. Demonstrates efficacy as expected. My big question is why are we doing trials like this against placebo? Surely a non-inferiority vs s/c secukinumab is more ethical. Abstr#0776 #ACR23 @RheumNow https://t.co/Usw0iwZEF5 https://t.co/DP6Gb4pF8a
Richard Conway ( View Tweet )
2 years 7 months ago
Do you think point of care #ultrasound should be mandatory in #rheumatologu #residency #training? @RheumNow @ACRheum #ACR23
Janet Pope ( View Tweet )
2 years 7 months ago
A good clinical trial should consist of not denying a standard of care comparator. Difficult to enrol in protocols requiring placebo in active disease. Maybe learn from #ped #rheum #RCTs where all get active #Rx then randomized to stop vs continue&trial designs. @RheumNow #ACR23 https://t.co/eQFEktsfBt
Janet Pope ( View Tweet )
2 years 7 months ago
A woman who knows how to integrate fashion into science. @ashira_md noted how TLR’s look like the Chanel brand @CHANEL #ACr23 @RheumNow @uptoTate @AWIRGROUP @gwenesta_melton #ScienceIsCool https://t.co/GQro9xR71W
TheDaoIndex @KDAO2011 ( View Tweet )
2 years 7 months ago
SLE Prosp Observational Cohort Study (SPOCS) reported realworld data on meds use in mod-to-severe SLE:
⬆️in GC dose in 1st 6mos then stable thru 36mos w/ stable antimalarials, mod⬆️in biologics, IS
Key message? Addt'l tx needed to avoid high GC doses
#ACR23 ABST0592 @RheumNow https://t.co/q5YGYKNG6S
sheila ( View Tweet )
2 years 7 months ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
2 years 7 months ago
CV events in women w/ ARDs pregnancies:
-2.0% of 19,340 pregnant ARDs
Adjusted relative risk:
-4 fold in ARD
-15 fold in primary APS
-6 fold in SLE
-SLE + APS 18 fold
25-30% occur in early post partum!
Need for continued vigilance after delivery
@RheumNow #ACR23 ABST0722 https://t.co/hLeN61WBnB
Aurelie Najm ( View Tweet )
2 years 7 months ago
